EverSource Wealth Advisors’s Bicycle Therapeutics BCYC Stock Holding History

EverSource Wealth Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$623	Buy	+147	New	+$674	﹤0.01%	4085
2026 Q1	–	Sell	-6	Closed	-$42	–	4397
2025 Q4	$42	Hold	6	–	–	﹤0.01%	4182
2025 Q3	$46	Buy	+6	New	+$45	﹤0.01%	4257
2025 Q2	–	Sell	-13	Closed	-$110	–	4261
2025 Q1	$110	Sell	13 -11	-46%	-$130	﹤0.01%	3815
2024 Q4	$336	Buy	24 +4	+20%	+$86	﹤0.01%	3313
2024 Q3	$453	Buy	+20	New	+$461	﹤0.01%	2893

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

EverSource Wealth Advisors's BCYC Position: Q2 2026 in Review

EverSource Wealth Advisors opened a new position in Bicycle Therapeutics (BCYC) in Q2 2026: 147 shares worth $623. The stake represents ﹤0.01% of the portfolio and ranks #4085 among its holdings. This is a return to the name: EverSource Wealth Advisors previously reported a position in BCYC as recently as Q4 2025.

EverSource Wealth Advisors first reported a position in BCYC in Q3 2024 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

EverSource Wealth Advisors held 147 shares of Bicycle Therapeutics worth $623 as of Q2 2026.
Bicycle Therapeutics was a new EverSource Wealth Advisors position in Q2 2026.
Bicycle Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4085 holding.
EverSource Wealth Advisors first reported a position in Bicycle Therapeutics in Q3 2024 and has held it in 6 quarters since.
103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.